← Back to Search

Radiation Therapy

SBRT for Kidney Cancer (AQuOS-RCC Trial)

N/A
Waitlist Available
Research Sponsored by Sunnybrook Health Sciences Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Histologic diagnosis of RCC where possible, or radiologic evidence of growth on surveillance
Medically inoperable or patient who refuses surgery
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years after completion of treatment
Awards & highlights
No Placebo-Only Group

Summary

This trial is investigating whether SBRT is an effective cancer treatment, and whether it improves quality of life.

Who is the study for?
This trial is for adults who can't have surgery or choose not to, with kidney tumors larger than 2.5cm or recurring after treatment. They should be diagnosed with renal cell carcinoma (RCC) if possible, or show tumor growth on scans.
What is being tested?
The study tests Stereotactic body radiotherapy (SBRT), a high-precision radiation therapy aimed at treating non-surgical patients with RCC to see how it affects their quality of life and cancer control.
What are the potential side effects?
While the side effects specific to SBRT in this trial are not listed, generally SBRT may cause fatigue, skin reactions, nausea, and potential damage to nearby organs depending on the site treated.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My kidney cancer diagnosis was confirmed by a biopsy or by growth seen on scans.
Select...
I cannot undergo surgery for medical reasons or I choose not to have surgery.
Select...
My cancer lesion is larger than 2.5cm or has come back after treatment.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years after completion of treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years after completion of treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Patient Quality of Life
Secondary study objectives
Cost-Effectiveness
Oncologic Outcomes
Treatment-Related Toxicity

Side effects data

From 2024 Phase 2 trial • 57 Patients • NCT03004183
21%
Fatigue
13%
Nausea
11%
Back pain
9%
Diarrhea
9%
Anemia
9%
Shortness of Breath
9%
Abdominal pain
7%
Kidney Injury and/or Infection
7%
Pneumonia
7%
Weight Loss
7%
Dyspnea
5%
Malnutrition, Hypercalcemia and Weakness
5%
Pneumothorax
5%
Intractable pain, back pain, hip pain
5%
Activated partial thromboplastin time prolonged
4%
Atrial fibrillation with rapid ventricular response
4%
Pleural effusion
2%
colitis
2%
Thrombocytopenia
2%
Respiratory failure
2%
Skin rash
100%
80%
60%
40%
20%
0%
Study treatment Arm
Single Arm

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: SBRTExperimental Treatment1 Intervention
RCC patients
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SBRT
2014
Completed Phase 2
~1060

Find a Location

Who is running the clinical trial?

Sunnybrook Health Sciences CentreLead Sponsor
674 Previous Clinical Trials
1,565,459 Total Patients Enrolled
Juravinski Cancer CenterOTHER
13 Previous Clinical Trials
2,315 Total Patients Enrolled
~3 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top